Trial reportAddiction biology2025
Deep Transcranial Magnetic Stimulation in Patients With Opioid Use Disorder: A Double-Blind, Placebo-Controlled Randomized Trial.
Trial report in Addiction biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06081985 (Efficacy of Deep Transcranial Magnetic Stimulation in Patients With Opioid Use Disorder), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Deep Transcranial Magnetic Stimulation in Patients With Opioid Use Disorder
Who cites it
3 citing papers in PubMed.
- Deep Transcranial Magnetic Stimulation in Patients With Opioid Use Disorder: A Double-Blind, Placebo-Controlled Randomized Trial.Addiction biology · 2025Trial
- Superior colliculus modulates the compulsion in a model of addiction with foot-shock.Translational psychiatry · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Opioid use disorder (OUD) is a chronic, relapsing brain disorder. The efficacy of brain stimulation methods in the treatment of OUD has been increasingly investigated. However, the efficacy of deep transcranial magnetic stimulation, namely, wide-volume TMS, in the treatment of OUD has not been investigated. The aim of this randomized, double-blind, sham-controlled add-on study was to evaluate the efficacy of wide-volume TMS using a double-cone coil in participants with OUD. A total of 55 OUD patients were recruited and randomized to receive either active or sham TMS. Active wide-volume TMS treatment was applied to the left dorsolateral prefrontal cortex (DLPFC) in the active TMS group using a double-cone coil, twice daily for 2 weeks, at a frequency of 10 Hz. Sham TMS was also applied to the same region in the placebo group using a placebo coil. Opioid Craving Visual Analogue Scale (OC-VAS), Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS) and Barratt Impulsiveness Scale-11 (BIS-11) were measured before treatment, at the end of treatment, and 2 months after treatment. A total of 21 patients from the active TMS group and 19 patients from the sham TMS group completed the study. Although the active TMS group exhibited more reduction in craving and a less pronounced increase in buprenorphine-naloxone dose during the treatment period compared to the sham group, these differences did not reach statistical significance. This study suggests that while wide-volume TMS using a double-cone coil applied to the left DLPFC was well tolerated, it did not produce statistically significant improvements in craving, depression, anxiety, or impulsivity when compared to the sham treatment. However, the observed trends warrant further investigation with larger sample sizes and refined protocols.
trial registrationTHIS TRIAL WAS REGISTERED AT CLINICALTRIALS.GOV (NCT06081985).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.